Skip to main content
Clinical Trials/NCT05980754
NCT05980754
Not yet recruiting
Not Applicable

Clinical Study on Exploring High Risk Factors Inducing the Progress of Diabetes

Peking University Third Hospital0 sites90 target enrollmentMay 20, 2024
ConditionsT2D

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
T2D
Sponsor
Peking University Third Hospital
Enrollment
90
Primary Endpoint
biochemical parameters including level of Glucose
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Explore the high related factors of impaired glucose tolerance through descriptive statistics and analysis of variance.

Detailed Description

This study is a cross-sectional study planned to include healthy individuals with a BMI within the normal range (18.5\<BMI\<24 kg/m2) (HbA1c ≤ 5.6%, n=18), pre diabetic patients (5.7% ≤ HbA1c ≤ 6.4%, n=36), and T2DM patients (HbA1c ≥ 6.5%, n=36) among individuals who meet the inclusion criteria and undergo annual physical examinations at the Physical Examination Center of the Third Hospital of Beijing Medical University. Collect the examination values related to demography and glucose metabolism balance of physical examination items, and carry out magnetic resonance imaging (MRI) imaging examination and oral glucose tolerance test (OGTT) results. Explore the high related factors of impaired glucose tolerance through descriptive statistics and analysis of variance.

Registry
clinicaltrials.gov
Start Date
May 20, 2024
End Date
December 30, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dongyang Liu

Principal Investigator

Peking University Third Hospital

Eligibility Criteria

Inclusion Criteria

  • The diagnostic criteria of the American diabetes Association (ADA) were used to determine the type of subjects: Group Healthy individuals: Glycated hemoglobin (HbA1c) ≤ 5.6%; Group Pre T2DM patients: 5.7% ≤ HbA1c ≤ 6.4%; Group T2DM patients: HbA1c ≥ 6.5% (for T2DM patients: this study needs to include first-time or previously diagnosed patients who have not used hypoglycemic drugs within 4 years and HBA1C ≤ 9.5%)Clinical diagnosis of Alzheimer's Disease.
  • Male weight ≥ 50kg, female weight ≥ 45kg, 18.5 \< BMI \< 24kg/m2
  • Age range from 40 years old (inclusive) to 65 years old (inclusive), with no less than one-third of either gender
  • Subjects voluntarily sign informed consent forms, can maintain good communication with researchers, and comply with the requirements of clinical trials

Exclusion Criteria

  • In the past month and currently taking glucocorticoids, steroids, thiazide diuretics, or atypical antipsychotic drugs
  • Some diseases that affect glucose tolerance: type 1 diabetes (T1DM), pancreatic exocrine disease, polycystic ovary syndrome and other endocrine diseases, autoimmune diseases, infection and trauma and other irritability factors
  • Diseases that may affect eating: mental illness, post gastrectomy, inflammatory bowel disease, uncontrolled thyroid disease.
  • Healthy subjects with a history of gestational diabetes or subjects with direct family members with a family history of diabetes
  • Pregnant or lactating women
  • Participate in any other clinical trials within 3 months prior to the trial
  • Blood donation or loss of ≥ 400mL within 8 weeks before the first cycle of the experiment
  • Clinically significant history of ECG abnormalities or family history of long QT syndrome (grandparents, parents, siblings) Suffering from any condition that significantly affects glucose absorption, distribution, metabolism, and excretion within 2 weeks prior to the experiment, or any condition that may pose a hazard to the subject, the detailed conditions are as follows:
  • History of inflammatory bowel disease, gastritis, ulcers, gastrointestinal or rectal bleeding
  • A significant history of gastrointestinal surgery (such as gastrectomy, gastroenterostomy, or intestinal resection),

Outcomes

Primary Outcomes

biochemical parameters including level of Glucose

Time Frame: through study completion, an average of 1 year

level of Glucose

biochemical parameters including level of insulin

Time Frame: through study completion, an average of 1 year

level of insulin

biochemical parameters including level of C-peptide

Time Frame: through study completion, an average of 1 year

level of C-peptide

Secondary Outcomes

  • Liver fat content(1 year)
  • pancreatic fat content(1 year)

Similar Trials